Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25321732 | 1.00 | PDE4B (0.59) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL25320873 | 1.00 | PDE4B (0.59) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL29475559 | 1.00 | PDE4B (0.59) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL1673519 | 0.94 | GPR119 (0.63) | PDE4BGPR119NAMPTLMNAMAPT | |
| SCHEMBL10162809 | 0.91 | GPR119 (0.58) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL25321447 | 0.91 | GPR119 (0.55) | PDE4BGPR119NAMPTLMNAMAPT | |
| SCHEMBL1673472 | 0.85 | GPR119 (0.51) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL18937651 | 0.85 | PDE4B (0.60) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL12321142 | 0.85 | PDE4B (0.60) | PDE4BGPR119TP53NAMPTLMNA | |
| SCHEMBL22988918 | 0.84 | PDE4B (0.58) | PDE4BTP53NAMPTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | PDE4B 1887/4885GPR119 867/4885TP53 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.